Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

University Hospital, Brest100 enrolled

Overview

The study will collect cases of MPN patients who also benefit from an anti-inflammatory immunotherapy for another disease. Efficacy and tolerability of the drug will be assessed in this population.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Myeloproliferative Neoplasm Inflammatory Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MyeloProliferative Neoplasm diagnosis * receiving or having received an immunotherapy targeting IL-1, IL-6, IL-17, IL-23 or TNF Exclusion Criteria: * Unable to consent

Locations (1)

Chu Brest

Brest, France

Outcomes

Primary Outcomes

Efficacy of the anti-inflammatory immunotherapy

Depending on the indication of the anti-inflammatory treatment, clinical efficacy will be assessed clinically as number of patients reaching complete (total disappearance of initial symptoms- diarrhea, arthritis, fever, skin lesions), partial (improvement of symptoms, but not total disappearance) or absence of response (the treatment did not improve the symptoms). Clinical judgement will be according to the physician appreciation.

Time frame: 1 year

Tolerability of the anti-inflammatory immunotherapy

Tolerability will be assessed as the number of reported unexpected side effects attributed to the treatment as judged by the caring physician, including treatment discontinuation

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.